Atai backs away from schizophrenia drug after trial failure

The company plans to direct resources away from a drug developed by subsidiary Recognify Life Sciences and toward Atai’s wholly owned, psychedelics-focused pipeline.

Group seeks industry-wide boycott of upcoming Africa Energies Summit – EnviroNews

March 11, 2026

FDA rejects Regenxbio treatment in another blow to gene therapy

FDA clears repurposed GSK drug for ultra-rare brain disease instead of autism

March 11, 2026

Source link

Atai backs away from schizophrenia drug after trial failure

Group seeks industry-wide boycott of upcoming Africa Energies Summit – EnviroNews

FDA clears repurposed GSK drug for ultra-rare brain disease instead of autism

Top African VC Funds Actively Investing Right Now (2025 Update)

Social housing and the future of Cape Town’s inner-city

Social housing and the future of Cape Town’s inner-city

Leave a Reply Cancel reply

RECOMMENDED NEWS

Musk’s AI startup seeks to raise $1 bn

Areen Development awards Boulevard Al Areen construction contract to Al Hamad Contracting

Shakib claims four as Bangladesh edge Zimbabwe

Dogecoin Edges Towards $0.2 Milestone as Dogecoin20 Hits $10M in Presale

POPULAR NEWS

Mahama attends Liberia’s 178th independence anniversary

Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

The world’s top 10 most valuable car brands in 2025

Top 10 African countries with the highest GDP per capita in 2025

Global ranking of Top 5 smartphone brands in Q3, 2024

Atai backs away from schizophrenia drug after trial failure

Related posts

Top African VC Funds Actively Investing Right Now (2025 Update)

Social housing and the future of Cape Town’s inner-city

Leave a Reply Cancel reply

RECOMMENDED NEWS

POPULAR NEWS